Following Moderna’s public rebuke of the FDA’s refusal to take up its application for a next-gen flu vaccine, the regulator has doubled down and accused Moderna of potentially putting patients at risk with its trial design.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Following Moderna’s public rebuke of the FDA’s refusal to take up its application for a next-gen flu vaccine, the regulator has doubled down and accused Moderna of potentially putting patients at risk with its trial design.